de Groot, S., Pijl, H., Charehbili, A., van de Ven, S., Smit, V. T. H. B. M., Meershoek-Klein Kranenbarg, E., . . . Kroep, J. R. (2019). Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01). Breast Cancer Res.
Citação norma Chicagode Groot, Stefanie, et al. "Addition of Zoledronic Acid to Neoadjuvant Chemotherapy Is Not Beneficial in Patients With HER2-negative Stage II/III Breast Cancer: 5-year Survival Analysis of the NEOZOTAC Trial (BOOG 2010-01)." Breast Cancer Res 2019.
Citação norma MLAde Groot, Stefanie, et al. "Addition of Zoledronic Acid to Neoadjuvant Chemotherapy Is Not Beneficial in Patients With HER2-negative Stage II/III Breast Cancer: 5-year Survival Analysis of the NEOZOTAC Trial (BOOG 2010-01)." Breast Cancer Res 2019.